• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients.
【24h】

Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients.

机译：激动性精神病患者的短期治疗中，肌注齐拉西酮2 mg和10 mg。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: There is a clear need for effective, well-tolerated intramuscular (i.m.) agents for the acute control of agitated psychotic patients. Currently used agents, including conventional antipsychotics and/or benzodiazepines, may be associated with distressing side effects such as extrapyramidal side effects and excessive sedation. OBJECTIVE: The objective of this study was to evaluate the efficacy and tolerability of the rapid-acting i.m. formulation of the novel antipsychotic ziprasidone in the treatment of inpatients with psychosis and acute agitation (DSM-IV diagnoses). METHOD: In a 24-hour, double-blind, fixed-dose clinical trial, patients were randomly assigned to receive up to 4 injections (every 2 hours p.r.n.) of 2 mg (N = 54) or 10 mg (N = 63) of ziprasidone i.m. The Behavioral Activity Rating Scale measured behavioral symptoms at baseline and the response to treatment up to 4 hours after the first i.m. injection. RESULTS: Ziprasidone i.m., 10 mg, rapidly reduced symptoms of acute agitation and was significantly more effective (p < .01) than the 2-mg dose up to 4 hours after the first injection. Patients were calmed but not excessively sedated, and over half were classed as responders 2 hours after the 10-mg dose. No acute dystonia or behavioral disinhibition was reported. One patient who received the 10-mg dose experienced the extrapyramidal side effect akathisia. CONCLUSION: Ziprasidone i.m., 10 mg, is rapidly effective and well tolerated in the short-term management of the agitated psychotic patient. Comparison with a study of identical design comparing 2-mg with 20-mg doses in patients with similar levels of psychopathology suggests that efficacy with 10 mg or 20 mg of ziprasidone i.m. is significant and dose related.
机译：背景：显然需要有效，耐受性良好的肌内（i.m.）药物来急性控制精神病患者。当前使用的药物，包括常规抗精神病药和/或苯二氮卓类药物，可能与令人烦恼的副作用如锥体束外副作用和过度镇静有关。目的：本研究的目的是评估速效i.m.的疗效和耐受性。新型抗精神病药物齐拉西酮的处方治疗精神病和急性躁动症患者的治疗（DSM-IV诊断）。方法：在一项24小时，双盲，固定剂量的临床试验中，患者被随机分配接受最多4次注射（每2小时一次）2 mg（N = 54）或10 mg（N = 63）齐拉西酮im行为活动能力评定量表在首次出院后4小时内测量基线时的行为症状和对治疗的反应。注射。结果：Ziprasidone i.m.（10 mg）可以迅速减轻急性躁动症状，并且在首次注射后的4小时内比2 mg剂量有效得多（p <.01）。患者恢复平静但未过度镇静，超过10毫克的剂量在2毫克后2小时被归类为反应者。没有急性肌张力障碍或行为抑制的报道。一名接受10毫克剂量的患者出现锥体束外副作用静坐症。结论：Ziprasidone i.m.，10 mg，在躁动性精神病患者的短期治疗中迅速有效且耐受性良好。与相同设计的研究比较，在精神病学水平相似的患者中将2 mg和20 mg剂量进行比较，表明使用10 mg或20 mg ziprasidone i.m的疗效。是重要的并且与剂量有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号